LASSBio-2389
LASSBio-2389 is a selective ROCK2 inhibitor with an IC50 of 0.051 μM and an IC50 of 1.143 μM against ROCK1. LASSBio-2389 reduces the viability of MDA-MB-231 cells and inhibits cell migration. LASSBio-2389 is applicable to the research of triple-negative breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2671377-38-9
- Formule: C18H18N4O4
- Masse moléculaire:354.36
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
|
ROCK1 1.143 μM (IC50) |
ROCK2 0.051 μM (IC50) |
LASSBio-2389 exhibits high passive permeability in gastrointestinal tract models, but shows no permeability in blood-brain barrier models[1].
LASSBio-2389 (30 μM; 24 h) reduces the viability of MDA-MB-231 cells[1].
LASSBio-2389 (0.1-100 μM; 24 h) potently inhibits the migration of MDA-MB-231 cells at concentrations as low as 0.1 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 triple-negative breast cancer cells
-
Concentration:30 μM
-
Incubation Time:24 h
-
Result:Reduced MDA-MB-231 cell viability by 26.2% (73.8% viability relative to vehicle control).
Chemical Information
-
CAS No. 2671377-38-9
-
Masse moléculaire 354.36
-
Formule C18H18N4O4
-
SMILES
O=C(C1=CC(OC)=C(OC)C(OC)=C1)N/N=C/C2=CC(C=NN3)=C3C=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)